Skip to main content

Table 2 Clinical characteristics by quartiles of serum adipsin levels in obese subjects

From: Association of circulating adipsin with nonalcoholic fatty liver disease in obese adults: a cross-sectional study

Variables

Serum adipsin level

p value for trend§

Quartile 1

Quartile 2

Quartile 3

Quartile 4

Sample size

290

291

291

291

 

Serum adipsin (ug/ml)

3.27 ± 0.64

4.45 ± 0.35

5.51 ± 0.46

8.30 ± 2.63

< 0.001

Age (years)

51.9 ± 7.2

52.6 ± 7.2

53.6 ± 7.5‡

54.8 ± 7.1‡

< .0001

Gender (male n, %)

74 (25.5)

75 (25.8)

75 (25.8)

75 (25.8)

1.000

BMI (kg/m2)

26.9 ± 2.7

27.1 ± 2.6

27.6 ± 3.3†

28.0 ± 3.3‡

< 0.001

Waist circumference (cm)

92.2 ± 6.2

93.2 ± 6.9

93.8 ± 7.3†

94.6 ± 7.4‡

< 0.001

Current smokers (n, %)

34 (11.7)

36 (12.4)

35 (12.0)

30 (10.3)

0.822

Systolic BP (mmHg)

132.3 ± 16.9

132.4 ± 17.6

133.9 ± 18.4

134.5 ± 18.3

0.864

Diastolic BP (mmHg)

78.5 ± 10.4

79.3 ± 10.2

79.4 ± 11.1

79.6 ± 10.7

0.599

Triglycerides (mmol/L)

1.42 (0.96–2.19)

1.61 (1.13–2.31)

1.43 (0.99–2.19)

1.61 (1.09–2.20)

0.128

Total cholesterol (mmol/L)

5.88 ± 1.08

5.86 ± 1.01

5.90 ± 1.07

5.92 ± 1.10

0.955

LDL-cholesterol (mmol/L)

3.67 ± 1.01

3.59 ± 0.95

3.73 ± 0.92

3.74 ± 1.01

0.491

HDL-cholesterol(mmol/L)

1.39 ± 0.30

1.36 ± 0.31

1.38 ± 0.28

1.34 ± 0.29

0.182

Fasting glucose (mmol/L)

6.40 ± 2.47

6.05 ± 1.52‡

5.98 ± 1.15‡

5.89 ± 0.98‡

< 0.001

2-h glucose (mmol/L)

9.23 ± 4.74

8.74 ± 3.65

8.69 ± 3.31†

8.57 ± 3.34†

0.039

HOMA-IR

3.09 (2.16–4.46)

2.89 (2.16–4.28)

2.65 (1.97–3.76) †

2.83(2.03–4.14)

0.035

ALT (U/L)

24.2 ± 12.2

24.9 ± 13.1†

25.8 ± 19.8

22.9 ± 12.3

0.107

AST (U/L)

21.7 ± 7.1

22.0 ± 6.5

23.4 ± 9.1

21.9 ± 6.2

0.030

GGT (U/L)

35.1 ± 23.9

35.0 ± 23.4

34.2 ± 23.3

32.3 ± 20.0

0.404

Body fat mass (kg)

23.6 ± 5.1

23.9 ± 5.0

24.2 ± 5.4

24.8 ± 5.6‡

0.003

FIB-4 value

0.90 ± 0.37

0.94 ± 0.52

0.98 ± 0.37

0.97 ± 0.36

0.608

Metabolic syndrome (n, %)

184 (63.5)

183 (63.1)

181 (62.2)

196 (67.4)

0.579

NAFLD (n, %)

169 (58.3)

175 (60.1)

167 (57.4)

146 (50.2) †

0.012

  1. Data are presented as the mean ± SD or median (interquartile range)
  2. BMI = body mass index; HOMA-IR = homeostasis model assessment of insulin resistance; FIB-4 = fibrosis-4 index
  3. §Adjusted for age and gender
  4. †p < 0.05compared with Q1 of serum adipsin
  5. ‡p < 0.01compared with Q1 of serum adipsin